Poland· PL-100492329
Rezzayo
A rezafungin acetate product containing rezafunginum, registered in Poland by Mundipharma GmbH. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Rezafungin acetate is registered in 10 of 19 countries.
Countries holding a registration under ATC J02AX08 (rezafungin acetate), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Rezafungin acetate · ATC J02AX08
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Rezafunginum
- Manufacturer
- Mundipharma GmbH
- Country
- Poland (PL)
- ATC code
- J02AX08
- ATC class
- Rezafungin acetate
- Defined daily dose
- 28.6 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rezafungin acetate in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumRezzayo 200 mgMundipharma
- SwitzerlandRezzayo 200 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungMundipharma Medical Company, Hamilton, Bermuda, Basel Branch
- CzechiaREZZAYOMundipharma Gesellschaft mit beschränkter Haftung, FRANKFURT
- SpainREZZAYO 200 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONMundipharma Gmbh
- FinlandREZZAYOMundipharma GmbH
- United KingdomRezzayo 200mg powder for concentrate for solution for infusion vialsNapp Pharmaceuticals Ltd
- IrelandREZZAYO 200 mg powder for concentrate for solution for infusionMundipharma GmbH
- IcelandRezzayoMundipharma GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rezzayo
- Liechtenstein · Rezzayo
- Norway · Rezzayo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0fe0be5-e8aa-420e-8718-a1b5387e9c98 GET /v1/drugs/c0fe0be5-e8aa-420e-8718-a1b5387e9c98?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania koncentratu roztworu do infuzji",
"source": "urpl",
"strength": "200 mg",
"packaging": "Rpz ¦ EU/1/23/1775/001 ¦ 152881\n1 fiol. 200 mg proszku",
"substance": "Rezafunginum 200 mg",
"common_name": "Rezafunginum",
"pl_product_id": "100492329",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about rezafungin acetate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.